The Endpoints 11: They’ve Got Mad Money And Huge Ambitions. It’s Time To Go Big Or Go Home
Read More
04/08/22
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022
In The News
Up And Down The Ladder: The Latest Comings And Goings
Read More
GSK’s Head Of Oncology Jumps To Boston Precision Medicine Startup
Read More
GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Read More
In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
Read More
GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
Read More
Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion
Read More
J.P. Morgan 39th Annual Healthcare Conference
Read More
Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0’
Read More
With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
Read More
Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0 — We’ll Just Have To Wait For The Details
Read More
Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
Read More
Scorpion, Seeking To Develop ‘Precision Medicine’ Drugs For Cancer, Debuts With $108m In Funding
Read More
What Can A Biotech Entrepreneur And A Top Scientist Come Up With On A Couple Of Shared Flights? Well…
Read More
Media
Discovery and characterization of a PI3KαH1047X mutant selective inhibitor with a best-in-class profile
Press Releases
The Endpoints 11: They’ve Got Mad Money And Huge Ambitions. It’s Time To Go Big Or Go Home
Read More
Up And Down The Ladder: The Latest Comings And Goings
Read More
GSK’s Head Of Oncology Jumps To Boston Precision Medicine Startup
Read More
GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Read More
In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
Read More
GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
Read More
Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion
Read More
J.P. Morgan 39th Annual Healthcare Conference
Read More
Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0’
Read More
With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
Read More
Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0 — We’ll Just Have To Wait For The Details
Read More
Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
Read More
Scorpion, Seeking To Develop ‘Precision Medicine’ Drugs For Cancer, Debuts With $108m In Funding
Read More
What Can A Biotech Entrepreneur And A Top Scientist Come Up With On A Couple Of Shared Flights? Well…
Read More